Nac 200 Akut 1 A Pharma (Acetylcysteine)

Acetylcysteine reduces mucus viscosity by breaking disulfide bonds within mucopolysaccharide glycoproteins. This chemical action decreases the elasticity of mucus, allowing ciliary movement and cough to more effectively transport secretions out of the respiratory tract, thereby improving airway patency.

The appropriate dose of Nac 200 Akut 1 A Pharma is determined by the prescribing healthcare professional based on the patient’s condition, age, weight and renal function. The prescriber will specify the exact regimen and any necessary adjustments.

Safety data for acetylcysteine in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Acetylcysteine is a thiol‑containing mucolytic that directly cleaves disulfide bonds, whereas other agents such as carbocisteine or ambroxol primarily modify mucus production or increase ciliary activity. Acetylcysteine’s antioxidant properties also provide additional benefits in certain pulmonary conditions.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

The medication is taken orally as directed by the prescriber. It may be administered with or without food, depending on the specific instructions provided. Swallow the tablet or capsule whole; do not crush or chew unless explicitly advised.

Serious adverse events, although rare, include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome, bronchospasm (particularly in asthmatic patients), significant hepatic enzyme elevation, and hematologic abnormalities like neutropenia. Immediate medical attention is required if any of these occur.

Patients with a known hypersensitivity to acetylcysteine or any of the product’s excipients should avoid its use. Caution is also advised for individuals with severe asthma, uncontrolled hepatic disease, or those receiving nitroprusside, due to the risk of enhanced hypotensive effects.